Who
Eric M. Dube
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Travere Therapeutics; Director, OnKure Therapeutics.
In numbers
- Trades disclosed
- 148
- Buys
- 0
- Sells
- 40
- Bought
- $0
- Sold
- $84.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 Jan 2019
- Last trade
- 17 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.6M101,691 at $64.59 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $442K6,802 at $64.95 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —108,493 at $0.00 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —108,493 at $0.00 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $2.5M108,493 at $23.34 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $2.5M108,493 at $23.34 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.6M101,691 at $64.59 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $442K6,802 at $64.95 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —195,841 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —195,841 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $4.6M195,841 at $23.34 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.3M99,716 at $63.26 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.1M96,125 at $63.64 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $4.6M195,841 at $23.34 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.3M99,716 at $63.26 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.1M96,125 at $63.64 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $2.2M95,666 at $23.34 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —95,666 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.9M63,498 at $61.99 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M28,796 at $62.66 | filing |
News
No headline names them, or the companies they trade most, lately.